Search for: "Rachel Sachs"
Results 1 - 20
of 82
Sorted by Relevance
|
Sort by Date
31 May 2016, 4:44 pm
If anyone is looking for a clear and comprehensive review of the ways in which patents can distort investment in innovation, as well as a summary of the literature on incentives "beyond IP", I highly recommend Rachel Sachs' new article Prizing Insurance: Prescription Drug Insurance as Innovation Incentive, forthcoming in the Harvard Journal of Law & Technology. [read post]
27 Jul 2015, 9:39 am
In Innovation Law and Policy: Preserving the Future of Personalized Medicine, Rachel Sachs (Petrie-Flom Fellow at Harvard Law) examines the intersection of IP with FDA regulation and health law, joining a growing body of scholarship that seeks to contextualize IP in a broader economic context. [read post]
9 Jun 2016, 3:30 am
Rachel Sachs, Prizing Insurance: Prescription Drug Insurance as Innovation Incentive, 30 Harv. [read post]
12 Apr 2015, 11:00 pm
The Petrie-Flom Center, Harvard Law School Rachel E. [read post]
22 Mar 2013, 10:16 am
*Rachel Tischler is a law school intern currently attending Brooklyn Law School. [read post]
12 Jan 2017, 7:30 am
Despite announcing in his first press conference that he would deal with a pharmaceutical industry “getting away with murder,” President-elect Donald Trump doesn’t seem to have a clear path for how he will reduce drug prices, said Rachel Sachs, associate professor of law at Washington University in St. [read post]
1 Feb 2019, 9:56 am
Sachs“The new proposal aims to eliminate rebates from pharmaceutical companies to pharmacy benefit managers (PBMs) in Medicare Part D and in Medicaid managed care organizations,” said Rachel Sachs, associate professor of law in the School of Law. [read post]
13 Feb 2018, 6:44 am
“Gone are some of President Trump’s older arguments that Medicare should negotiate drug prices, or that drug importation should be permitted more widely,” said Rachel Sachs, associate professor of law in the School of Law. [read post]
21 Nov 2011, 12:01 pm
The first one was Evan Sachs… for [allegedly] stabbing a child randomly at Dave and Busters. [read post]
11 Mar 2020, 3:30 am
Lemley, Lisa Larrimore Ouelette, and Rachel Sachs, The Medicare Innovation Subsidy, N.Y.U. [read post]
11 Aug 2016, 11:46 am
Thanks to Rachel Sachs for the following summary of the opening plenary session at IPSC! [read post]
22 Jun 2020, 11:45 am
Sachs on Reimbursement Policy and Innovation Incentives for COVID-19 July 23: Lisa Larrimore Ouellette on Innovation Policy Pluralism and COVID-19. [read post]
6 Dec 2019, 4:07 am
For the employees of Goldman Sachs, there is now a rule as well. [read post]
14 May 2018, 8:56 am
Sachs“The administration’s blueprint contains dozens of proposals and over a hundred potential questions to explore in the future,” said Rachel Sachs, associate professor of law in the School of Law, who has written extensively on drug policy and pricing. [read post]
4 Oct 2018, 12:18 pm
Sachs“In the U.S., we give innovator pharmaceutical companies some period of exclusivity after their product comes to market, before which a biosimilar drug can be approved on the strength of the innovator drugs application in the first instance,” said Rachel Sachs, associate professor of law in the School of Law and an expert on drug policy and pricing. [read post]
31 Aug 2016, 7:02 am
Sachs“We should not think of ‘price controls’ as a four-letter word,” said Rachel Sachs, associate professor of law and an expert on drug regulation and health law. [read post]
30 Nov 2016, 1:21 pm
“One of the most troubling provisions in the previous draft of the bill would’ve created a program for the use of ‘clinical experience’ evidence in drug approvals,” said Rachel Sachs, associate professor of law and an expert on drug regulation and health law. [read post]
25 Oct 2018, 9:30 pm
But the latest health care legislation introduced in Congress and the federal government’s larger policy plan are unlikely to drive the innovations necessary to improve the health of the American people, argues Rachel Sachs, a professor at Washington University School of Law. [read post]
9 Oct 2017, 9:09 am
Sachs“The best-price rule is not as serious a problem as drug manufacturers might perceive it to be,” said Rachel Sachs, associate professor of law and co-author of “Innovative Contracting for Pharmaceuticals and Medicaid’s Best-Price Rule,” recently published in the Journal of Health Politics, Policy and Law. [read post]
3 Aug 2017, 7:30 am
“One particularly noteworthy dimension of the 21st Century Cures Act was the way in which it originally moved through the House of Representatives,” said Rachel Sachs, associate professor of law. [read post]
